Nadolol
- Generic Name
- Nadolol
- Brand Names
- Corgard
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO4
- CAS Number
- 42200-33-9
- Unique Ingredient Identifier
- FEN504330V
- Background
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.
Nadolol was granted FDA approval on 10 December 1979.
- Indication
Nadolol is indicated to treat angina pectoris and hypertension. Another product formulated with bendroflumethiazide is indicated to treat hypertension.
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Gastroesophageal variceal hemorrhage prophylaxis, Hypertension, Migraine, Thyrotoxicosis
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
- Conditions
- High Blood PressureMigraine HeadachesChest Pain
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 34
- Registration Number
- NCT00960245
A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis
- Conditions
- Variceal BleedingCirrhosis
- Interventions
- Procedure: Ligation of varices
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- National Science Council, Taiwan
- Target Recruit Count
- 140
- Registration Number
- NCT00921349
Oral Nadolol for the Treatment of Adults With Mild Asthma
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Invion, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00670267
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 120
- Registration Number
- NCT00567216
- Locations
- 🇨🇳
Veteran General Hospital-Taipei, Taipei city, Taiwan, China
Secondary Prophylaxis After Variceal Bleeding in Non-Responders
- Conditions
- Gastrointestinal HemorrhagePortal HypertensionCirrhosis
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2007-03-21
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Recruit Count
- 50
- Registration Number
- NCT00450164
- Locations
- 🇪🇸
Unidad de Sangrantes, HSCSP, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.